Treatment of refractory pulmonary arterial hypertension with inhaled epoprostenol in an infant with congenital heart disease

Congenital Heart Disease

Volumn 2, Issue 3, 2007, Pages 194-198

  Kovach, Joshua ^a   Ibsen, Laura ^a   Womack, Michael ^b   Steusse, David ^b   Law, Yuk M ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b St Luke's Children's Hospital   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

Congenital heart disease; Epoprostenol; Pulmonary arterial hypertension; Pulmonary vasodilators

Indexed keywords

BUMETANIDE; DOPAMINE; FUROSEMIDE; NITRIC OXIDE; OXYGEN; PROSTACYCLIN; SILDENAFIL;

ALKALINIZATION; ARTICLE; BLALOCK TAUSSIG ANASTOMOSIS; CASE REPORT; CHILD; CONGENITAL HEART DISEASE; CONTINUOUS INFUSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; GREAT VESSELS TRANSPOSITION; HEART HEMODYNAMICS; HEART VENTRICLE SEPTUM DEFECT; HUMAN; MALE; NEWBORN HYPOXIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SEDATION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; BLOOD VESSEL PROSTHESIS; EPOPROSTENOL; HEART DEFECTS, CONGENITAL; HEART SEPTAL DEFECTS, VENTRICULAR; HUMANS; HYPERTENSION, PULMONARY; INFANT; LIGATION; MALE; PULMONARY ARTERY; TRANSPOSITION OF GREAT VESSELS;

EID: 34250171137     PISSN: 1747079X     EISSN: 17470803     Source Type: Journal    
DOI: 10.1111/j.1747-0803.2007.00097.x     Document Type: Article

References (32)

1. 2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction. Eur Surg Res. 1993; 25: 329-340.
2. Zwissler B, Welte M, Messmer K. Effects of inhaled prostacyclin as compared with inhaled nitric oxide on right ventricular performance in hypoxic pulmonary vasoconstriction. J Cardiothorac Vasc Anesth. 1995; 9: 283-289.
3. Fortier S, DeMaria RG, Lamarche Y, et al. Inhaled prostacyclin reduces cardiopulmonary bypass-induced pulmonary endothelial dysfunction via increased cyclic adenosine monophosphate levels. J Thorac Cardiovasc Surg. 2004; 128: 109-116.
4. Haraldsson A, Kieler-Jensen N, Ricksten SE. Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: A pharmacodynamic study. J Cardiothorac Vasc Anesth. 1996; 10: 864-868.
5. Mikhail G, Gibbs JS, Richardson M, et al. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Soc Cardiol. 1997; 18: 1499-1504.
6. Haraldsson A, Kieler-Jensen N, Nathorst-Westfelt U, Bergh CH, Ricksten SE. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest. 1998; 114: 780-786.
7. Langer F, Wendler O, Wilhelm W, Tscholl D, Schafers HJ. Treatment of a case of acute right heart failure by inhalation of iloprost, a long-acting prostacyclin analogue. Eur Acad Anaesthesiol. 2001; 18: 770-773.
8. Hache M, Denault A, Belisle S, et al. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery. J Thorac Cardiovasc Surg. 2003; 125: 642-649.
9. De Wet CJ, Affleck DG, Jacobsohn E, et al. Inhaled prostacyclin is safe, effective and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2004; 127: 1058-1067.
10. Bindl L, Fahnenstich H, Peukert U. Aerosolised prostacyclin for pulmonary hypertension in neonates. Arch Dis Child Fetal Neonatal Ed. 1994; 71: F214-F216.
11. Pappert D, Busch T, Gerlach H, Lewandowski K, Radermacher P, Roissant R. Aerosolized prostacyclin versus inhaled nitric oxide in children with acute respiratory distress syndrome. Anesthesiology. 1995; 82: 1507-1511.
12. Zwissler B, Rank N, Jaenicke U, et al. Selective pulmonary vasodilation by inhaled prostacyclin in a newborn with congenital heart disease and cardiopulmonary bypass. Anesthesiology. 1995; 82: 1512-1516.
13. Soditt V, Aring C, Groneck P. Improvement of oxygenation induced by aerosolized prostacyclin in a preterm infant with persistent pulmonary hypertension of the newborn. Inten Care Med. 1997; 23: 1275-1278.
14. Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr. 2002; 141: 830-832.
15. Dahlem PD, van Aalderen WM, de Neef M, Dijkgraaf MG, Bos AP. Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Pediatr Crit Care. 2004; 32: 1055-1060.
16. Bando K, Turrentine MW, Sharp TG, et al. Pulmonary hypertension after operations for congenital heart disease: Analysis of risk factors and management. J Thorac Cardiovasc Surg. 1996; 112: 1600-1609.
17. D'Angeli MA, Goetzman BW. Intratracheal administration of pulmonary vasodilator agents. Pediatr Pulmonol. 1992; 14: 85-90.
18. Turanlahti MI, Laitinen PO, Sarna SJ, Pesonen E. Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension. Heart. 1998; 79: 169-174.
19. Schermuly RT, Ghofrani HA, Enke B, et al. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am J Respir Crit Care Med. 1999; 160: 1500-1506.
20. Ghofrani HA, Widermann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 2002; 136: 515-522.
21. Kerins DM, Murray R, Fitzgerald GA. Prostacyclin and prostaglandin E1: molecular mechanisms and therapeutic utility. Prog Hemost Thromb. 1991; 10: 307-337.
22. Armstead WM. Role of nitric oxide and cAMP in prostaglandin-induced pial arterial vasodilation. Am J Physiol. 1995; 268: H1436-H1440.
23. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991; 43: 109-142.
24. Eckly AE, Lugnier C. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Br J Pharmacol. 1994; 113: 445-450.
25. Razandi M, Pedram A, Rubin T, Levin ER. PGE2 and PGI2 inhibit ET-1 secretion from endothelial cells by stimulating particulate guanylate cyclase. Am J Physiol. 1996; 270: H1342-H1349.
26. Hermon M, Golej J, Burda G, Marx M, Trittenwein G, Pollak A. Intravenous prostacyclin mitigates inhaled nitric oxide rebound effect: A case control study. Artif Organs. 1999; 23: 975-978.
27. Hill LL, Pearl RG. Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. J Appl Physiol. 1999; 86: 1160-1164.
28. Miyaji K, Nagata N, Miyamoto T, Kitahori K. Combined therapy with inhaled nitric oxide and intravenous epoprostenol (prostacyclin) for critical pulmonary perfusion after the Fontan procedure. J Thorac Cardiovasc Surg. 2003; 125: 437-439.
29. Saji K, Sakuma M, Suzuki J, et al. Efficacy of acute inhalation of nitric oxide in patients with primary pulmonary hypertension using chronic use of continuous epoprostenol infusion. Circ J. 2005; 69: 335-338.
30. Forrest IA, Small T, Corris PA. Effect of nebulized epoprostinol (prostacyclin) on exhaled nitric oxide in patients with pulmonary hypertension due to congenital heart disease and in normal controls. Clin Sci. 1999; 97: 99-102.
31. Zhang X, Hintze TH. cAMP signal transduction cascade, a novel pathway for the regulation of endothelial nitric oxide production in coronary blood vessels. Arterioscler Thromb Vasc Biol. 2001; 21: 797-803.
32. Ozken M, Dweik RA, Laskowski D, Arroliga AC, Erzurum SC. High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy. Lung. 2002; 179: 233-243.